Choosing HCV Genotype 1 Therapy: Treat Now, or Wait?

At current estimated costs, waiting for interferon-free regimens was not cost-effective compared with using available IFN-based new DAAs.

In a short period, preferred therapy for hepatitis C virus (HCV) genotype 1 infection has changed from peginterferon plus ribavirin, to peginterferon and ribavirin plus direct-acting antivirals (DAAs), to DAAs without interferon (IFN) that are slated for FDA approval by early 2015. With such rapid changes, clinicians are asking whether patients should undergo treatment with IFN-based DAAs now or wait for IFN-free regimens.

This study compared the cost-effectiveness of IFN-based new DAAs with previous telaprevir and boceprevir–based regimens as well as IFN-free regimens in treatment-naive patients with HCV genotype 1. Investigators designed a decision analysis model to estimate the quality-adjusted life years (QALYs), cost, and incremental co…

Reviewing Author

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

Choosing HCV Genotype 1 Therapy: Treat Now, or Wait?

Topics

Reviewing Author